KR101993393B1 - 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 - Google Patents

옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 Download PDF

Info

Publication number
KR101993393B1
KR101993393B1 KR1020120124724A KR20120124724A KR101993393B1 KR 101993393 B1 KR101993393 B1 KR 101993393B1 KR 1020120124724 A KR1020120124724 A KR 1020120124724A KR 20120124724 A KR20120124724 A KR 20120124724A KR 101993393 B1 KR101993393 B1 KR 101993393B1
Authority
KR
South Korea
Prior art keywords
seq
auxintomodulin
derivative
diabetes
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020120124724A
Other languages
English (en)
Korean (ko)
Other versions
KR20140058104A (ko
Inventor
김진선
김대진
이상현
정성엽
권세창
Original Assignee
한미약품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한미약품 주식회사 filed Critical 한미약품 주식회사
Priority to KR1020120124724A priority Critical patent/KR101993393B1/ko
Priority to UAA201504676A priority patent/UA117570C2/uk
Priority to SG10201703732VA priority patent/SG10201703732VA/en
Priority to EA201892383A priority patent/EA037956B1/ru
Priority to NZ738835A priority patent/NZ738835A/en
Priority to ES13853226T priority patent/ES2802099T3/es
Priority to HK15112811.5A priority patent/HK1211856B/xx
Priority to NZ708105A priority patent/NZ708105A/en
Priority to TW110124452A priority patent/TWI755341B/zh
Priority to AU2013342324A priority patent/AU2013342324B2/en
Priority to BR122019024272-0A priority patent/BR122019024272B1/pt
Priority to HUE13853226A priority patent/HUE049240T2/hu
Priority to US14/440,653 priority patent/US20150299282A1/en
Priority to BR122021003984-4A priority patent/BR122021003984B1/pt
Priority to PL13853226T priority patent/PL2916860T3/pl
Priority to JP2015540614A priority patent/JP6363613B2/ja
Priority to DK13853226.2T priority patent/DK2916860T3/da
Priority to PCT/KR2013/009990 priority patent/WO2014073845A1/en
Priority to PE2015000594A priority patent/PE20151420A1/es
Priority to CN201380069535.8A priority patent/CN104918632B/zh
Priority to SG11201503420QA priority patent/SG11201503420QA/en
Priority to LTEP13853226.2T priority patent/LT2916860T/lt
Priority to EP20151111.0A priority patent/EP3679944B1/en
Priority to TW109122403A priority patent/TWI754980B/zh
Priority to MX2018012968A priority patent/MX378848B/es
Priority to TW107133431A priority patent/TWI741218B/zh
Priority to ARP130104070A priority patent/AR093386A1/es
Priority to MYPI2015001149A priority patent/MY173828A/en
Priority to HRP20200925TT priority patent/HRP20200925T1/hr
Priority to EA201590759A priority patent/EA031928B1/ru
Priority to PT138532262T priority patent/PT2916860T/pt
Priority to MX2015005699A priority patent/MX360335B/es
Priority to TW102140248A priority patent/TWI645856B/zh
Priority to UAA201802409A priority patent/UA130270C2/uk
Priority to SG10202110636WA priority patent/SG10202110636WA/en
Priority to EP13853226.2A priority patent/EP2916860B1/en
Priority to NZ748034A priority patent/NZ748034B2/en
Priority to CA2890329A priority patent/CA2890329C/en
Priority to BR112015010203-4A priority patent/BR112015010203B1/pt
Publication of KR20140058104A publication Critical patent/KR20140058104A/ko
Priority to IL238631A priority patent/IL238631B/en
Priority to CL2015001207A priority patent/CL2015001207A1/es
Priority to PH12015501009A priority patent/PH12015501009B1/en
Priority to ZA2015/03999A priority patent/ZA201503999B/en
Priority to AU2018200138A priority patent/AU2018200138B2/en
Priority to US15/960,205 priority patent/US10550168B2/en
Priority to JP2018123263A priority patent/JP6666959B2/ja
Priority to PH12018501424A priority patent/PH12018501424B1/en
Application granted granted Critical
Publication of KR101993393B1 publication Critical patent/KR101993393B1/ko
Priority to AU2019275590A priority patent/AU2019275590B2/en
Priority to JP2020028080A priority patent/JP7050834B2/ja
Priority to IL273305A priority patent/IL273305B/en
Priority to JP2022016603A priority patent/JP7341263B2/ja
Priority to ARP220102265A priority patent/AR126851A2/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020120124724A 2012-11-06 2012-11-06 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 Active KR101993393B1 (ko)

Priority Applications (52)

Application Number Priority Date Filing Date Title
KR1020120124724A KR101993393B1 (ko) 2012-11-06 2012-11-06 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
UAA201504676A UA117570C2 (uk) 2012-11-06 2013-06-11 Спосіб лікування діабету або діабету, спричиненого ожирінням, або ускладнень при діабеті
SG10201703732VA SG10201703732VA (en) 2012-11-06 2013-11-06 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
EA201892383A EA037956B1 (ru) 2012-11-06 2013-11-06 Композиция для лечения диабета или диажирения, содержащая конъюгат аналога оксинтомодулина
NZ738835A NZ738835A (en) 2012-11-06 2013-11-06 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
ES13853226T ES2802099T3 (es) 2012-11-06 2013-11-06 Una composición para el tratamiento de la diabetes que comprende un análogo de oxintomodulina
HK15112811.5A HK1211856B (en) 2012-11-06 2013-11-06 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
NZ708105A NZ708105A (en) 2012-11-06 2013-11-06 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
TW110124452A TWI755341B (zh) 2012-11-06 2013-11-06 治療糖尿病或糖胖症之包括調酸素類似物之組成物
AU2013342324A AU2013342324B2 (en) 2012-11-06 2013-11-06 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
BR122019024272-0A BR122019024272B1 (pt) 2012-11-06 2013-11-06 composição para a prevenção ou tratamento de diabetes complicações diabéticas ou diabesidade e uso de composição para a preparação de um medicamento para a prevenção ou tratamento de diabetes, complicações diabéticas ou diabesidade
HUE13853226A HUE049240T2 (hu) 2012-11-06 2013-11-06 Oxintomodulin analógot tartalmazó készítmény diabetes kezelésére
US14/440,653 US20150299282A1 (en) 2012-11-06 2013-11-06 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
BR122021003984-4A BR122021003984B1 (pt) 2012-11-06 2013-11-06 Composição para a prevenção ou tratamento de diabetes, complicações diabéticas ou diabesidade, uso da composição para a preparação de um medicamento para a prevenção ou tratamento de diabetes, complicações diabéticas ou diabesidade
PL13853226T PL2916860T3 (pl) 2012-11-06 2013-11-06 Kompozycja do leczenia cukrzycy zawierająca analog oksyntomoduliny
JP2015540614A JP6363613B2 (ja) 2012-11-06 2013-11-06 オキシントモジュリン誘導体を含む糖尿病又は肥満性糖尿病の治療用組成物
DK13853226.2T DK2916860T3 (da) 2012-11-06 2013-11-06 En sammensætning til behandling af diabetes, som omfatter oxyntomodulinanalog
PCT/KR2013/009990 WO2014073845A1 (en) 2012-11-06 2013-11-06 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
PE2015000594A PE20151420A1 (es) 2012-11-06 2013-11-06 Una composicion para tratar diabetes o diabesidad que comprende un analogo de oxintomodulina
CN201380069535.8A CN104918632B (zh) 2012-11-06 2013-11-06 治疗糖尿病或糖胖病的包括胃泌酸调节素类似物的组合物
SG11201503420QA SG11201503420QA (en) 2012-11-06 2013-11-06 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
LTEP13853226.2T LT2916860T (lt) 2012-11-06 2013-11-06 Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą
EP20151111.0A EP3679944B1 (en) 2012-11-06 2013-11-06 A composition for treating diabetes comprising oxyntomodulin analog
TW109122403A TWI754980B (zh) 2012-11-06 2013-11-06 治療糖尿病或糖胖症之包括調酸素類似物之組成物
MX2018012968A MX378848B (es) 2012-11-06 2013-11-06 Una composicion para tratar diabetes o diabesidad que comprende un analogo de oxintomodulina
TW107133431A TWI741218B (zh) 2012-11-06 2013-11-06 治療糖尿病或糖胖症之包括調酸素類似物之組成物
ARP130104070A AR093386A1 (es) 2012-11-06 2013-11-06 Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento
MYPI2015001149A MY173828A (en) 2012-11-06 2013-11-06 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
HRP20200925TT HRP20200925T1 (hr) 2012-11-06 2013-11-06 Pripravak za liječenje dijabetesa koji uključuje analog oksintomodulina
EA201590759A EA031928B1 (ru) 2012-11-06 2013-11-06 Композиция для лечения диабета или диажирения, содержащая конъюгат аналога оксинтомодулина
PT138532262T PT2916860T (pt) 2012-11-06 2013-11-06 Composição para o tratamento da diabetes ou da diabesidade compreendo um análogo de oxintomodulina
MX2015005699A MX360335B (es) 2012-11-06 2013-11-06 Una composicion para tratar diabetes o diabesidad que comprende un analogo de oxintomodulina.
TW102140248A TWI645856B (zh) 2012-11-06 2013-11-06 治療糖尿病或糖胖症之包括調酸素類似物之組成物
UAA201802409A UA130270C2 (uk) 2012-11-06 2013-11-06 Композиція для профілактики або лікування діабету, діожиріння або ускладнень при діабеті, яка містить аналог оксинтомодуліну
SG10202110636WA SG10202110636WA (en) 2012-11-06 2013-11-06 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
EP13853226.2A EP2916860B1 (en) 2012-11-06 2013-11-06 A composition for treating diabetes comprising oxyntomodulin analog
NZ748034A NZ748034B2 (en) 2012-11-06 2013-11-06 A Composition For Treating Diabetes Or Diabesity Comprising Oxyntomodulin Analog
CA2890329A CA2890329C (en) 2012-11-06 2013-11-06 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
BR112015010203-4A BR112015010203B1 (pt) 2012-11-06 2013-11-06 uso de uma composição para a preparação de um medicamento para a prevenção ou o tratamento de diabetes, complicações diabéticas ou diabesidade compreendendo um conjugado analogo da oxintomodulina
IL238631A IL238631B (en) 2012-11-06 2015-05-04 A preparation containing an analogue of oxyntomodulin for the treatment of diabetes or diabetes accompanied by obesity
CL2015001207A CL2015001207A1 (es) 2012-11-06 2015-05-06 Composición para prevenir o tratar diabetes, diabesidad o complicaciones diabéticas, que comprende un análogo de oxintomodulina; y uso de la composición.
PH12015501009A PH12015501009B1 (en) 2012-11-06 2015-05-06 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
ZA2015/03999A ZA201503999B (en) 2012-11-06 2015-06-04 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
AU2018200138A AU2018200138B2 (en) 2012-11-06 2018-01-08 A Composition For Treating Diabetes or Diabesity Comprising Oxyntomudulin Analog
US15/960,205 US10550168B2 (en) 2012-11-06 2018-04-23 Composition for treating diabetes or diabesity comprising oxyntomodulin analog
JP2018123263A JP6666959B2 (ja) 2012-11-06 2018-06-28 オキシントモジュリン誘導体を含む糖尿病又は肥満性糖尿病の治療用組成物
PH12018501424A PH12018501424B1 (en) 2012-11-06 2018-07-03 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
AU2019275590A AU2019275590B2 (en) 2012-11-06 2019-12-04 A Composition For Treating Diabetes Or Diabesity Comprising Oxyntomudulin Analog
JP2020028080A JP7050834B2 (ja) 2012-11-06 2020-02-21 オキシントモジュリン誘導体を含む糖尿病又は肥満性糖尿病の治療用組成物
IL273305A IL273305B (en) 2012-11-06 2020-03-15 A preparation containing an analog of oxyntomodulin for the treatment of diabetes or diabetes accompanied by obesity
JP2022016603A JP7341263B2 (ja) 2012-11-06 2022-02-04 オキシントモジュリン誘導体を含む糖尿病又は肥満性糖尿病の治療用組成物
ARP220102265A AR126851A2 (es) 2012-11-06 2022-08-23 Composición para prevenir o tratar diabetes, diabesidad o complicaciones diabéticas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120124724A KR101993393B1 (ko) 2012-11-06 2012-11-06 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물

Publications (2)

Publication Number Publication Date
KR20140058104A KR20140058104A (ko) 2014-05-14
KR101993393B1 true KR101993393B1 (ko) 2019-10-01

Family

ID=50684885

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020120124724A Active KR101993393B1 (ko) 2012-11-06 2012-11-06 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물

Country Status (29)

Country Link
US (2) US20150299282A1 (https=)
EP (2) EP2916860B1 (https=)
JP (4) JP6363613B2 (https=)
KR (1) KR101993393B1 (https=)
CN (1) CN104918632B (https=)
AR (2) AR093386A1 (https=)
AU (3) AU2013342324B2 (https=)
BR (3) BR112015010203B1 (https=)
CA (1) CA2890329C (https=)
CL (1) CL2015001207A1 (https=)
DK (1) DK2916860T3 (https=)
EA (2) EA037956B1 (https=)
ES (1) ES2802099T3 (https=)
HR (1) HRP20200925T1 (https=)
HU (1) HUE049240T2 (https=)
IL (2) IL238631B (https=)
LT (1) LT2916860T (https=)
MX (2) MX360335B (https=)
MY (1) MY173828A (https=)
NZ (2) NZ708105A (https=)
PE (1) PE20151420A1 (https=)
PH (2) PH12015501009B1 (https=)
PL (1) PL2916860T3 (https=)
PT (1) PT2916860T (https=)
SG (3) SG11201503420QA (https=)
TW (4) TWI754980B (https=)
UA (2) UA117570C2 (https=)
WO (1) WO2014073845A1 (https=)
ZA (1) ZA201503999B (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240686A1 (es) 2011-06-10 2024-04-10 Hanmi Science Co Ltd Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)
PE20230404A1 (es) 2011-06-17 2023-03-07 Hanmi Science Co Ltd Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
PE20151421A1 (es) 2012-11-06 2015-09-24 Hanmi Pharm Ind Co Ltd Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
AU2015242657B2 (en) * 2014-03-31 2020-05-21 Hanmi Pharm. Co., Ltd. Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TWI684458B (zh) * 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
MY185334A (en) 2014-12-30 2021-05-06 Hanmi Pharm Ind Co Ltd Glucagon derivatives with improved stability
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
EA201890058A1 (ru) * 2015-06-30 2018-07-31 Ханми Фарм. Ко., Лтд. Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CN108136043B (zh) 2015-10-01 2022-09-06 诺和诺德股份有限公司 蛋白质缀合物
EP3359191A4 (en) * 2015-10-05 2019-05-29 Merck Sharp & Dohme Corp. ANTIBODY PEPTIDE CONJUGATES WITH AGONISTEACTIVITY ON GLUCAGON RECEPTORS AND GLUCAGON-LIKE PEPTIDE-1
WO2017062271A2 (en) 2015-10-06 2017-04-13 Merck Sharp & Dohme Corp. Antibody drug conjugate for anti-inflammatory applications
WO2017116204A1 (ko) 2015-12-31 2017-07-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
EP3407916B1 (en) 2016-01-29 2023-12-20 Merck Sharp & Dohme LLC Phosphonate linkers and their use to facilitate cellular retention of compounds
KR101887576B1 (ko) * 2016-04-15 2018-08-13 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
KR102005457B1 (ko) * 2016-06-29 2019-07-30 한미약품 주식회사 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도
RU2764197C1 (ru) 2016-09-23 2022-01-14 Ханми Фарм. Ко., Лтд. Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение
CN108299554B (zh) * 2017-01-13 2021-05-25 博瑞生物医药（苏州）股份有限公司 胃泌酸调节素类似物
AR111341A1 (es) 2017-03-23 2019-07-03 Hanmi Pharm Ind Co Ltd Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
CN106986924A (zh) * 2017-03-23 2017-07-28 中国药科大学 胃泌酸调节素（oxm）类似物及其应用
WO2019066603A1 (ko) * 2017-09-29 2019-04-04 한미약품 주식회사 효력이 향상된 지속성 단백질 결합체
WO2019171352A2 (en) * 2018-03-08 2019-09-12 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity
CN121591873A (zh) * 2018-07-19 2026-03-03 D&D制药技术股份有限公司 包括多肽的药物组合物
WO2020017919A1 (ko) * 2018-07-19 2020-01-23 한미정밀화학주식회사 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법
KR20200135618A (ko) * 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
US11929171B2 (en) 2018-10-18 2024-03-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for evaluation and treatment of glycemic dysregulation and atherosclerotic cardiovascular disease and applications thereof
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
WO2020128967A2 (en) * 2018-12-19 2020-06-25 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity
EP3939990A4 (en) * 2019-02-15 2023-05-24 Hanmi Fine Chemical Co., Ltd. NOVEL INTERMEDIATE FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND PROCESS FOR THE PRODUCTION THEREOF
KR102094103B1 (ko) * 2019-05-08 2020-03-27 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 당뇨병 예방 또는 치료용 약학 조성물
CN114853908B (zh) * 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
WO2022104394A1 (en) * 2020-11-16 2022-05-19 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for diagnostic assessment and treatment of insulin resistance and hyperglycemia
CN121064327A (zh) * 2024-06-03 2025-12-05 信达生物制药(苏州)有限公司 Gipr、glp1r和/或gcgr的调节剂及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075393A2 (en) * 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
US20120003712A1 (en) * 2009-03-20 2012-01-05 Hanmi Holdings Co., Ltd. Method for preparing a site-specific physiologically active polypeptide conjugate

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
JP3895109B2 (ja) 1998-03-06 2007-03-22 中外製薬株式会社 蛋白非添加製剤
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
US20090238838A1 (en) 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
ATE555133T1 (de) * 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
CA2589800A1 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
RU2485135C2 (ru) 2005-06-13 2013-06-20 Импиэриэл Инноувейшнс Лимитид Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты)
GB0511986D0 (en) 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
CN101389648B (zh) 2006-02-22 2013-07-17 默沙东公司 肽胃泌酸调节素衍生物
US8334365B2 (en) 2006-06-07 2012-12-18 Human Genome Sciences, Inc. Albumin fusion proteins
GB0624868D0 (en) 2006-12-13 2007-01-24 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CN101730523A (zh) 2007-07-10 2010-06-09 伊莱利利公司 GLP-1-Fc融合蛋白质制剂
KR20100069651A (ko) 2007-09-11 2010-06-24 몬도바이오테크 래보래토리즈 아게 Ｈｃｍｖ 감염의 치료를 위한 치료제로서의 ｂｕｂｕｃ 및 임의의 ｅａａ－ｍａｒｔ１（２６－３５）의 용도
US8980830B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
AU2009210570B2 (en) 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
WO2009155257A1 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
EP2300037B1 (en) 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2010013012A2 (en) 2008-08-01 2010-02-04 Lund University Bioscience Ab Novel polypeptides and uses thereof
WO2010033220A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
EP2341942A1 (en) 2008-09-19 2011-07-13 Nektar Therapeutics Polymer conjugates of therapeutic peptides
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
CN102325539A (zh) 2008-12-19 2012-01-18 印第安纳大学研究及科技有限公司 基于酰胺的胰高血糖素超家族肽前药
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
EP2408814B1 (en) 2009-03-20 2018-11-21 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
EP2496249B1 (en) 2009-11-03 2016-03-09 Amylin Pharmaceuticals, LLC Glp-1 receptor agonist for use in treating obstructive sleep apnea
EP2509997B1 (en) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
AR079345A1 (es) * 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
EP2552950A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
RU2580317C2 (ru) * 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CN101974077A (zh) 2010-09-15 2011-02-16 南京瑞年天平医药科技有限公司 一种新颖的多肽化合物
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
KR101767570B1 (ko) * 2010-10-26 2017-08-14 한미사이언스 주식회사 항 비만 펩타이드의 지속형 결합체
CN102010473A (zh) 2010-11-10 2011-04-13 曹鹏 重组胃泌酸调节素融合蛋白及其制备和应用
SG191252A1 (en) 2010-12-22 2013-07-31 Marcadia Biotech Inc Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
JP6118500B2 (ja) 2011-02-28 2017-04-19 ローム アンド ハース エレクトロニック マテリアルズ エルエルシーＲｏｈｍ ａｎｄ Ｈａａｓ Ｅｌｅｃｔｒｏｎｉｃ Ｍａｔｅｒｉａｌｓ ＬＬＣ フォトレジスト組成物、およびフォトリソグラフィパターンを形成する方法
KR101161526B1 (ko) 2011-05-16 2012-07-02 숭실대학교산학협력단 연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법
PE20240686A1 (es) 2011-06-10 2024-04-10 Hanmi Science Co Ltd Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)
PE20230404A1 (es) 2011-06-17 2023-03-07 Hanmi Science Co Ltd Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
BR112014025951A2 (pt) 2012-04-19 2017-07-11 Opko Biologics Ltd variantes de oxintomodulina de longa ação e métodos de produção do mesmo
CA2877358A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
PE20151421A1 (es) * 2012-11-06 2015-09-24 Hanmi Pharm Ind Co Ltd Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina
JP6137046B2 (ja) 2014-05-09 2017-05-31 信越化学工業株式会社 単量体、高分子化合物、レジスト材料及びパターン形成方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120003712A1 (en) * 2009-03-20 2012-01-05 Hanmi Holdings Co., Ltd. Method for preparing a site-specific physiologically active polypeptide conjugate
WO2011075393A2 (en) * 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists

Also Published As

Publication number Publication date
BR112015010203A8 (pt) 2019-11-26
BR122019024272B1 (pt) 2021-05-18
MY173828A (en) 2020-02-24
TWI741218B (zh) 2021-10-01
PL2916860T3 (pl) 2020-11-02
ES2802099T3 (es) 2021-01-15
UA130270C2 (uk) 2026-01-07
JP6363613B2 (ja) 2018-07-25
CA2890329C (en) 2024-01-23
JP2020079301A (ja) 2020-05-28
MX2015005699A (es) 2016-02-05
TW201422232A (zh) 2014-06-16
US20180237490A1 (en) 2018-08-23
NZ708105A (en) 2018-06-29
TW202144394A (zh) 2021-12-01
CN104918632B (zh) 2017-10-31
MX360335B (es) 2018-10-29
JP7050834B2 (ja) 2022-04-08
CN104918632A (zh) 2015-09-16
HUE049240T2 (hu) 2020-09-28
PH12018501424B1 (en) 2022-04-06
JP7341263B2 (ja) 2023-09-08
SG10201703732VA (en) 2017-06-29
US10550168B2 (en) 2020-02-04
TWI645856B (zh) 2019-01-01
AU2019275590B2 (en) 2022-01-20
PH12018501424A1 (en) 2019-04-01
US20150299282A1 (en) 2015-10-22
HK1211856A1 (en) 2016-06-03
AU2018200138B2 (en) 2019-09-12
PH12015501009A1 (en) 2015-07-27
NZ738835A (en) 2020-03-27
DK2916860T3 (da) 2020-06-15
AU2019275590A1 (en) 2020-01-02
AU2018200138A1 (en) 2018-02-01
WO2014073845A1 (en) 2014-05-15
EA201892383A1 (ru) 2019-03-29
HRP20200925T1 (hr) 2020-09-18
JP2015536943A (ja) 2015-12-24
TW201900206A (zh) 2019-01-01
SG10202110636WA (en) 2021-11-29
EP2916860A4 (en) 2016-06-22
AU2013342324B2 (en) 2018-02-22
PT2916860T (pt) 2020-07-02
SG11201503420QA (en) 2015-05-28
BR112015010203B1 (pt) 2021-05-18
EA037956B1 (ru) 2021-06-15
IL273305B (en) 2021-10-31
TWI755341B (zh) 2022-02-11
EA031928B1 (ru) 2019-03-29
KR20140058104A (ko) 2014-05-14
EP3679944A1 (en) 2020-07-15
MX378848B (es) 2025-03-11
TW202041528A (zh) 2020-11-16
BR112015010203A2 (pt) 2017-08-22
CA2890329A1 (en) 2014-05-15
JP2022048398A (ja) 2022-03-25
IL238631B (en) 2020-04-30
BR122021003984B1 (pt) 2022-07-12
PH12015501009B1 (en) 2019-03-06
JP2018162298A (ja) 2018-10-18
CL2015001207A1 (es) 2015-07-03
IL273305A (en) 2020-04-30
EP2916860B1 (en) 2020-03-11
ZA201503999B (en) 2016-07-27
NZ748034A (en) 2020-10-30
EP2916860A1 (en) 2015-09-16
EA201590759A1 (ru) 2015-12-30
IL238631A0 (en) 2015-06-30
EP3679944B1 (en) 2022-03-30
AR093386A1 (es) 2015-06-03
AR126851A2 (es) 2023-11-22
AU2013342324A1 (en) 2015-05-28
UA117570C2 (uk) 2018-08-27
TWI754980B (zh) 2022-02-11
JP6666959B2 (ja) 2020-03-18
LT2916860T (lt) 2020-07-10
PE20151420A1 (es) 2015-09-24

Similar Documents

Publication Publication Date Title
KR101993393B1 (ko) 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
JP6345216B2 (ja) オキシントモジュリンと免疫グロブリン断片とを含む結合体及びその用途
TWI802396B (zh) 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
RU2768853C1 (ru) Композиция для лечения гиперлипидемии, содержащая производное оксинтомодулина
RU2624129C2 (ru) Способ получения комплекса физиологически активного полипептида
HK1211856B (en) A composition for treating diabetes or diabesity comprising oxyntomodulin analog
HK1238162A1 (en) Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
NZ748034B2 (en) A Composition For Treating Diabetes Or Diabesity Comprising Oxyntomodulin Analog

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20121106

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171106

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 20121106

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181024

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190401

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190620

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190621

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20220530

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20220530

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240522

Start annual number: 6

End annual number: 6